Nemaura Medical Present Positive Interim Clinical Trial Results Of Its sugarBEAT System

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura"), a medical device company developing the sugarBEAT® CGM System as a minimally invasive, wireless continuous glucose monitoring system, announced today that it has conducted a further interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients, and have determined a reduction in MARD from 18% to less than 11.8%. MARD is the Mean Absolute Relative Difference between finger-stick measurements and CGM sensor glucose values. A lower MARD indicates higher accuracy.

Help employers find you! Check out all the jobs and post your resume.